PTGX biotech catalysts & pipeline

PROTAGONIST THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

2026

· A U.S. regulatory decision is anticipated in 2026, followed by commercial launch this year, if FDA approval is granted.

~Feb ‘27

~Feb ‘27 ICONIC - PsA 2 10 Ph3, n ~ 750, in biologic exposed active psoriatic arthritis

~Jan ‘28

~Jan ‘28 ICONIC - CD 13 Ph 2/3, n ~ 1092, in Crohn's disease